| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.005 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.005 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.097 | 0.005 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.094 | 0.006 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.006 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.087 | 0.006 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.007 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.15 | 0.007 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.007 |